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Recombinant human growth hormone exacerbates chronic puromycin
aminonucleoside nephropathy in rats. Growth failure is a cardinal
feature of chronic renal failure in children. Administration of recombi-
nant human growth hormone (rhGH) ameliorates this problem but may
adversely affect the kidney and hasten the progression to end-stage
renal disease. We conducted experiments to examine the impact of
rhGH on the severity of chronic puromycin aminonucleoside (PAMN)
nephropathy in rats. The glomerulopathy was induced by serial injec-
tions of PAMN over a 12 week period. Experimental animals (N = 6)
received rhGH, 0.5 mg per dose, three times weekly, while control rats
(N = 6) received hormone vehicle. rhGH had no effect on weight gain,
hematocrit, or blood pressure in rats with the experimental renal
disease. Urinary protein excretion increased approximately 50% in
rhGH-treated rats with chronic PAMN nephropathy compared to
untreated animals between four to eight weeks of the observation
period. After 12 weeks, the inulin clearance was significantly lower in
rhGH-treated rats, 0.26 0.05 versus 0.50 0.06 ml/minll00 g body wt
in control PAMN animals, P < 0.05. Compared to untreated rats with
PAMN nephropathy, administration of rhGH increased the extent of
segmental glomerulosclerosis from 11 3 to 46 9% (P < 0.005) and
elevated the tubulointerstitial injury score from 0.5 0.1 to 1.4 0.4 (P
<0.05). Furthermore, glomerular hypertrophy was enhanced in ani-
mals with chronic PAMN nephropathy given rhGH, as evidenced by a
larger glomerular planar area, 9.2 0.3 x l0— versus 11.9 0.5 x l0-
mm2, P < 0.005. The renal cortical malondialdehyde content was higher
in rhGH-treated rats with chronic PAMN nephropathy, 2.33 0.13
versus 1.78 0.06 nmol/mg protein in untreated animals with glomer-
ular disease, P < 0.05. In normal rats with intact kidneys, rhGH
administration (N = 4) increased glomerular filtration rate and glomer-
ular planar area without altering blood pressure, proteinuria, renal
cortical malondialdehyde content, or glomerular or tubulointerstitial
damage, compared to untreated animals (N = 4). We conclude that
administration of rhGH to rats with chronic PAMN nephropathy
exacerbates the severity of the renal functional and structural injury in
response to the epithelial cell toxin. These data suggest that caution
should be exercised when prescribing rhGH for the treatment of short
stature in children with chronic renal failure, especially those with
glomerulopathies and persistent, severe nephrotic range proteinuria.
One of the most important complications of chronic renal
failure (CRF) in children is growth retardation [1]. The etiology
of this problem is multifactorial including insufficient caloric
intake, metabolic acidosis and renal osteodystrophy [2]. Al-
though plasma levels of growth hormone (Gil) and insulin-like
growth factor I (IGF-I) are within the normal range in pediatric
patients with CRF, circulating uremic inhibitors or end organ
responsiveness may interfere with the growth-promoting action
of these peptide hormones [1, 2].
The availability of recombinant human growth hormone
(rhGH) has prompted a reassessment of the role of GH in the
pathophysiology of short stature in children with CRF. Admin-
istration of rhGH for three weeks to rats with 5/6 nephrectomy
enhances somatic growth compared to untreated uremic coun-
terparts [3]. rhGH treatment for 6 to 12 months to prepubertal
children with CRF consistently improves growth velocity with-
out undue acceleration in bone maturation [4—6].
Recently, there has been concern that GH may aggravate
kidney disease and hasten the progression to end-stage renal
failure. Transgenic mice carrying the bovine GH gene fused to
the metallothionein-I promoter develop increased proteinuria
and glomerulosclerosis [7]. The structural changes are associ-
ated with enhanced mesangial production of type IV collagen,
laminin and heparan sulfate proteoglycans [8]. The severity of
injury following renal ablation is attenuated in a mutant strain of
dwarf rats that are selectively deficient in GH [9]. Finally,
although rhGH administration for eight weeks to rats with 5/6
nephrectomy does not cause any deterioration in renal function,
glomerular hypertrophy and glomerulosclerosis are increased in
treated animals [10].
It seems prudent to clarify the potential nephrotoxic effects of
rhGH prior to embarking on widespread clinical use of this
costly agent for the treatment of short stature in pediatric
patients with CRF. Therefore, we conducted the following
studies to assess the effect of rhGH on the course and severity
of chronic puromycin aminonucleoside (PAMN) nephropathy,
an experimental glomerulopathy characterized by heavy pro-
teinuria and renal insufficiency.
Methods
Animals
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Male Sprague-Dawley rats were purchased from Taconic
Farms (Germantown, New York, USA). They were housed in
an animal facility that was maintained at 25°C with a 12 hour
light-dark cycle. They were provided free access to water and
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standard rodent laboratory chow, containing 22% protein (Pu-
rina Mills, St. Louis, Missouri, USA). Because the pattern of
weight gain was similar in the two groups of rats with chronic
PAMN nephropathy, pair feeding was not employed in these
studies. The rats weighed 110 to 130 g at the initiation of the
experimental protocols.
Disease model
Chronic PAMN nephropathy was induced over 12 weeks
using the method described by Grond, Weening and Elema [11].
Briefly, rats were given serial subcutaneous injections of
PAMN, 2 mg/100 g body weight per dose, on days 1, 8, 15, 29,
43, 57, and 71. The toxin was dissolved in 0.9% NaCI at a
concentration of 10 mg/mi.
Rats with chronic PAMN nephropathy and a cohort of
normal rats with intact kidney function were randomly assigned
to an experimental group that received rhGH and a control
group given sham injections. The following four groups of rats
were studied:
Group IA (N = 6): PAMN nephropathy + vehicle
Group lB (N = 6): PAMN nephropathy + rhGH
Group hA (N 4): Normal rats + vehicle
Group IIB (N = 4): Normal rats + rhGH
rhGH was dissolved in phosphate buffered saline (PBS), pH
7.4, to a final concentration of 2.5 mg/mI. Aliquots, containing
the amount of rhGH needed for the administration of the
hormone to all experimental animals on a given day, were
stored frozen at —20°C. Therefore, the rhGH solution was
thawed only once, ensuring stability of the drug for the entire
12-week study period. Experimental rats received 0.2 ml of the
rhGH-PBS solution (0.5 mg of rhGH) as a subcutaneous injec-
tion three times per week for 12 weeks; control animals were
given an equal volume of the vehicle.
Rats were weighed biweekly and blood pressure was mea-
sured each month in the awake conscious state using a tail cuff
plethysmograph apparatus (Narco BioSystems, Houston,
Texas, USA). Every two weeks, animals were placed in indi-
vidual metabolic cages (Nalge, Rochester, New York, USA) to
enable collection of 24-hour urine samples for determination of
urinary osmolality, protein and creatinine concentrations. Rats
were given free access to water but not food while they were in
the metabolic cages. Each month, a fasting blood sample was
obtained at the completion of the urine collection for measure-
ment of hematocrit, serum Nat, creatinine, cholesterol, triglyc-
eride, and albumin concentrations.
Inulin clearance
At the end of the 12-week observation period, rats were
anesthetized with mactin (100 mg/kg body wt) and placed on a
heated animal operating table. The body temperature was
monitored with a YSI telethermometer and maintained at 36.5
to 37.5°C throughout the study. A tracheostomy was per-
formed, and the left external jugular vein was cannulated with
PE-50 polyethylene tubing for infusion of [3H]-inulin. A supra-
pubic cystotomy was performed for the collection of urine into
tared test tubes. Following preparation of the animal, 0.2 ml of
a solution containing 12.5 mCi [3H}-inulin/ml was injected as a
priming dose, followed by infusion of the same solution at a rate
of 0.12 mI/hr. After a 30-minute equilibration period, three
timed 30-minute urine collections were made, and midpoint
blood specimens were obtained via the cut tail vein. Serum and
urinary activities of [3H]-inulin were determined with a liquid
scintillation counter (LKB Rackbeta). Inulin and creatinine
clearances were calculated from the standard equation and the
data are expressed as ml per mm per 100 g body weight.
Histopathology examination
Rats were killed at the completion of the clearance studies.
The kidneys were immersion-fixed in a 10% formalin solution
and stained with hematoxylin-eosin and periodic acid-Schiff
reagents. Segmental sclerosis was defined as localized collapse
of capillary lumina and replacement with eosinophiic hyalin-
ized material, occasionally accompanied by adhesions to Bow-
man's capsule. The number of segmentally sclerosed glomeruli
was expressed as a percentage of the total number of glomeruli
which exceeded 250 in each sample. The tubules and intersti-
tium were examined for dilation, intratubular casts and tubular
atrophy, interstitial infiltration with mononuclear cells, and
replacement with fibrosis. The degree of tubulointerstitial
changes was graded on a scale from 0 to 3+ as follows: 0,
normal kidney; 1+, mild abnormalities affecting <25% of the
renal parenchyma; 2+, moderate, 25 to 50% involvement; and
3+, severe, >50% of the kidney manifested abnormalities.
Glomerular planar area was determined using a computerized
digitizing pad (Micro-plan II, Laboratory Computer Systems,
Inc., Monsanto Corp., Natick, New York, USA) and surveying
40 to 50 glomeruli in each kidney specimen. Glomeruli through-
out the cortex that were not globally sclerosed and that had
clear delineation of the hilar region were included in this
analysis.
Analytic methods
Serum Nat, glucose, creatinine, cholesterol and triglyceride
and urinary Na and creatinine determinations were made
using an automated analyzer (Beckman, Fullertown, California,
USA). Serum albumin levels were assayed with the bromcresol
green binding reagent (Sigma Chemical Co., St. Louis, Mis-
souri, USA), and absorbance was monitored at 628 nm. Urinary
protein concentration was measured using the Coomassie blue
binding reagent (Bio-Rad, Richmond, California, USA) while
urinary osmolality was determined with a vapor pressure os-
mometer (Wescor, Logan, Utah, USA).
Portions of the renal cortex were homogenized in 1.15% KCI
solution (1:9 wtlvol) for assay of malondialdehyde content as
described by Ohkawa, Ohishi and Yagi [121. A reaction mixture
containing 0.2 ml of sample, 0.2 ml of 8.1% sodium dodecyl
sulfate, 1.5 ml of 20% acetic acid adjusted to pH 3.5 with
NaOH, and 1.5 ml of 0.8% aqueous solution of thiobarbituric
acid was brought up to 4 ml with distilled water. The mixture
was heated for 60 minutes at 95°C and then cooled with tap
water, after which 1 ml of water and 5 ml of a mixture of
n-butanol and pyridine (15:1, vollvol) were added. The sample
was shaken vigorously and centrifuged at 4,000 rpm for 10
minutes, and the organic layer was removed. Absorbance was
measured at 532 nm, using 1,1,3,3-tetramethoxypropane as a
standard. The renal cortical lipid peroxide level was expressed
as nmollmg protein.
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Group LB Group IIB
Group IA (N = 6) Group hA (N = 4)(N = 6) PAMN + (N = 4) Normal +
PAMN rhGH Normal rhGH
Weight g
Pre 123±2 125±2 118±3 125±3
4 week 287 10 292 4 273 14 288 6
8 week 355 6 357 4 380 20 400 15
12 week 358 7 354 9 435 28 460 17
BPmm Hg
Pre 93±2 100±2 99±8 103±9
4week 134±4 131±3 120±5 114±3
8 week 131 3 147 2 127 5 123 3
12 week 139 1 141 1 124 3 129 5
Hematocrit %
Pre 44±1 47±1 44±1 43±1
4 week 50 1 49 1 49 1 49 1
8 week 52 1 53 1 52 1 50 1
l2week 38±2 38±3 51±2 54±1
Glucose mg/dl
Pre 199±1 94±6a 181±12 156±11
4week 135±8 142±4 87±6 86±3
8week 97±2 97±5 102±3 129±5
l2week 78±3 80±3 111±5 105±7
Statistical analysis
The differences between groups were analyzed using Stu-
dent's t-test and analysis of variance where appropriate. The
experimental findings were considered statistically significant if
P < 0.05.
Results
Administration of rhGH did not increase weight gain or
hematocrit in rats with chronic PAMN nephropathy (Table 1).
In addition, despite the presence of impaired renal function,
rhGH therapy did not cause sustained hyperglycemia in animals
with PAMN-induced glomerular disease. Except for the eight-
week time point when BP was higher in rats in Group IB, 147
2 versus 131 3 mm Hg in animals in Group IA, (P < 0.001),
rhGH injections did not cause sustained hypertension in rats
with renal disease.
The biochemical features of the nephrotic syndrome are
summarized in Table 2. Administration of rhGH to rats with
chronic PAMN nephropathy did not aggravate the hyperlipid-
emia or hypoalbuminemia observed during the course of the
glomerulopathy. Urinary protein excretion was elevated by
approximately 50% in rhGH-treated rats with PAMN nephrop-
athy (Group IB) between four to eight weeks of the study period
(Fig. 1). However, at the completion of the protocol, there was
no difference in proteinuria between the two groups with
PAMN nephropathy.
Urinary osmolality was lower in rats in Group IB, 682 83,
than in Group IA, 905 60 mOsm/kg (P = 0.05). In addition,
rhGH treatment of animals with chronic PAMN nephropathy
was associated with an increased fractional excretion of Na,
0.66 0.15 (Group IB) versus 0.28 0.04% (Group IA), P <
0.05 (Table 3).
Prior to 12 weeks, the creatinine clearance was similar in
Group LB Group IIB
Group IA (N = 6) Group hA (N = 4)(N = 6) PAMN + (N = 4) Normal +
PAMN rhGH Normal rhGH
Albumin g/dl
Pre 3.55 0.01 3.77 0.03" 3.52 0.07 3.57 0.04
4 week 3.88 0.06 3.66 0.06 4.00 0.04 3.98 0.11
8 week 2.40 0.10 2.20 0.08 3.98 0.07 4.03 0.09
12 week 1.62 0.06 1.63 0.06 3.11 0.19 3.77 0.40
Cholesterol
mg/d!
Pre 126±4 132±6 89±7 91±3
4week 123±4 153±9a 69±5 90±8
8 week 345 24 429 40 74 6 87 10
12 week 688 48 707 37 62 7 87 7
Triglycerides
mg/dl
Pre 90±8 %±6 55±8 48±4
4week 50±2 52±5 63±8 82±3
8 week 191 23 236 28 75 12 101 8
12 week 504 53 632 85 72 11 87 9
Creatinine
mgldl
Pre 0.58 0.02 0.57 0.04 0.43 0.03 0.40 0.04
4 week 0.62 0.02 0.53 0.02 0.53 0.03 0.40 0.04
8 week 0.62 0.02 0.67 0.02 0.55 0.03 0.58 0.03
12 week 0.68 0.05 1.04 0.18 0.68 0.06 0.58 0.03
Time, weeks
Fig. 1. Urinary protein excretion (mg124 hr) during the course of the
study in normal and PAMN nephropathy rats. Symbols are: (0) normal
rats + vehicle; (•) normal rat + rhGH; (0) chronic PAMN nephropa-
thy + vehicle; (U) chronic PAMN nephropathy + rhGH. * P < 0.01,
PAMN + rhGH vs. PAMN + vehicle.
Groups IA and lB (Fig. 2). After 12 weeks, the creatinine
clearance was reduced in rhGH-treated rats with PAMN ne-
phropathy, 0.24 0.05 compared to 0.34 0.03 mI/mm/tOO g
body wt in control PAMN rats. This finding was confirmed by
measuring the inulin clearance, 0.50 0.06 in Group IA versus
0.26 0.05 ml/min/100 g body wt in Group IB, P < 0.02 (Fig.
3). Total kidney weight was comparable in untreated PAMN
Table 1. General animal data: PAMN nephropathy versus normal
rats
Table 2. Biochemical features: PAMN nephropathy versus normal
rats
Results are mean SEM.P< 0.001 vs. Group IA
*
Results are mean SEM.
a P< 0.03 vs. Group IA
b P < 0.001 vs. Group IA
600
500
0 400x..
C
•5c%, 300
200
C
100
0
0 4 8 12
1284 Trachtman et a!: Growth hormone and PAMN nephropathy
Group IIB
Group IA Group lB Group hA (N = 4)(N = 6) (N = 6) (N = 4) Normal +
PAMN PAMN + rhGH Normal rhGH
Osmolality
mOsm/kg
Pre 968 82 822 123 848 55 1024 287
Final 905 60 682 83 847 142 849 192
FENA %
Pre 0.49 0.04 0.53 0.04 0.56 0.03 0.56 0.10
Final 0.28 004 0.66 0.15c 0.35 0.11 0.32 0.06
Results are mean SEM.
Abbreviation is FENA, fractional excretion of sodium.
aP = 0.05 vs. Group lB. preb P < 0.01 vs. Group IA, pre
P < 0.05 vs. Group 1A, final
0 4 8 12
Time, weeks
Fig. 2. Creatinine clearance (ml/minhlOO g body WI) during the 12 week
course of the study in normal and PAMN nephropathy rats. Symbols
are: (0) normal rats + vehicle; (•) normal rat + rhGH; (0) chronic
PAMN nephropathy + vehicle; () chronic PAMN nephropathy +
rhGH.
nephropathy rats, 4.6 0.2 versus 4.8 0.2 g in rhGH-treated
rats with PAMN-induced glomerulopathy. Thus, the difference
in inulin clearance between the two groups with PAMN ne-
phropathy persisted if the GFR was expressed per g kidney
weight, 0.44 0.06 (Group IA) versus 0.21 0.05 (Group IB),
P < 0.02.
Renal histopathology studies indicated that administration of
rhGH to rats with chronic PAMN nephropathy worsened the
parenchymal injury. The percentage of segmentally sclerosed
glomeruli was higher in Group 18, 46 9%, than in Group IA,
11 3 (P < 0.005); the tubutointerstitial injury score paralleled
the glomerular damage, that is, 1.4 0.4 in Group lB versus 0.5
0.1 in Group IA (P < 0.04) (Table 4). Furthermore, the
glomerular planar area was enlarged in rats with chronic PAMN
nephropathy given rhGH (Group IB), 11.9 0.5 compared to
9.2 0.3 x iO mm2 in untreated animals in Group IA (P <
0.005; Fig. 4). Figure 5 illustrates representative examples of
the renal parenchyma in animals with chronic PAMN nephrop-
athy that were provided vehicle or rhGH injections.
The renal cortical malondialdehyde content was significantly
• 1.00
5
C
Ce
a)
C.)
C
C
Fig. 3. Inulin clearance (m!/min/100 g body WI) after 12 weeks in
normal and PAMN nephropathy rats. Symbols are: (0) untreated; (0)
rhGH-treated. * P < 0.02, normal rats + rhGH vs. normal rats +
vehicle; ** p < 0.02, PAMN nephropathy + rhGH vs. PAMN nephrop-
athy + vehicle.
Segmental
glomerulosclerosisc
Tubulointerstitial
injuryd
GrouplA(N= 6) 11 3 0.5
PAMN
GrouplB(N=6) 46±9a 1404b
PAMN ÷ rhGH
Group hA (N = 4) 0 0
Normal
Group IIB (N = 4) 0 0
Normal + rhGH
Results are mean SEM.
ap < 0.005 vs. Group IA
b P < 0.04 vs. Group IA
Data provided as percentage of total number of glomeruli
d Data provided as average score on 0 to 3 + scale
greater in the rhGH-treated animals in Group IB, 2.33 0.13
than in rats in Group IA, 1.78 0.06 nmol/mg protein, P < 0.05.
The administration of rhGH to intact rats with normal kidney
function (Group IIB) had no demonstrable effect on somatic
growth, blood pressure, hematocrit or serum glucose concen-
tration compared to normal rats receiving no therapy (Group
hA; Table I). rhGH did not alter the serum albumin, choles-
terol, triglycerides or creatinine concentration in normal rats
(Table 2). In addition, there was no increase in urinary protein
excretion in Group 118 animals (Fig. 1). Urinary osmolality and
fractional excretion of Na were comparable in animals in
Groups IIA and JIB (Table 3).
Although there was no rhGH-induced alteration in creatinine
clearance (Fig. 2), the inulin clearance was greater in Group
IIB, 0.79 0.06, than in Group hA, 0.65 0.08 mI/mm 100 g
body wt (P < 0.02; Fig. 3). Hormonal therapy did not promote
glomerulosclerosis or tubulointerstitial damage in the animals in
Group JIB compared to the untreated rats in Group hA (Table
4 and Fig. 6). However, rhGH treatment did expand the
glomerular planar area from 4.6 0.3 (Group hA) to 5.8 0.4
Table 3. Urinary features: PAMN nephropathy versus normal rats
0.75
0.50
0.25
0.00
0.6
Normal Chronic PAMN
OS
0.5
0.4
0.3
0.2
0.1
0.0
Table 4. Renal histopathology: PAMN vs. normal rats
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Normal Chronic PAMN
Fig. 4. Glomerular planar area (x 1O mm2) in normal and PAMN
nephropathy rats. Symbols are: (0) vehicle treated; (0) columns,
rhGH treated. * P < 0.03, normal rats + rhGH vs. normal rats +
vehicle. ** P < 0.005, PAMN nephropathy + rhGH vs. PAMN
nephropathy + vehicle.
x 1o mm2 (Group JIB) (P < 0.03; Fig. 4). Finally, rhGH
administration did not promote lipid peroxidation in normals
rats. The renal cortical malondialdehyde was 1.34 0.09 in the
rats in Group IJA and 1.29 0.09 nmol/mg protein in rhGH-
treated normal rats in Group JIB.
Discussion
The results of this study indicate that administration of rhGH
to rats with chronic PAMN nephropathy exacerbates renal
functional and structural damage induced by this epithelial cell
toxin. This was manifested as a decline in GFR after 12 weeks,
increased glomerular hypertrophy, worsening of glomeruloscle-
rosis and increased tubular atrophy, interstitial infiltration with
mononuclear cells and fibrosis. rhGH treatment promoted
increased lipid peroxidation of the renal parenchyma. In normal
rats, rhGH treatment caused markedly different changes in
renal structure and function. Thus, although there was no
change in proteinuna or renal cortical malondialdehyde con-
tent, glomerular planar area and inulin clearance were in-
creased.
It is important to acknowledge the magnitude of the rhGH
dose that was provided to rats in Groups lB and IIB. The
animals received approximately 3 mg/kg/week of the hormone,
tenfold greater than the standard dose of rhGH given to children
with short stature, that is, 0.3 mg/kg/week [13]. A twofold larger
dose was used in a previous study investigating the impact of
GH in rats with CRF [10]. The rationale for its use is to facilitate
the detection of an adverse effect of rhGH within the time frame
of the experimental regimen. In addition, provision of a large
dose ensures that a pharmacologic level of GH is achieved in
the plasma and eliminates any confounding effect of antibody
production by rats to rhGH. The fact that rats with normal renal
function tolerated the administration of rhGH without overt
sequelae suggests that the hormone was free of systemic
toxicity and that the adverse effects of rhGH were confined to
the kidney.
Substantial data indicate the potential harm to the kidney that
may result from rhGH treatment. Mesangial accentuation and
glomerulosclerosis develop in mice that are transgenic for
bovine GH [7]. Initially, there is increased number of centrolob-
ular glomerular cells [14], followed by enhanced production and
accumulation of extracellular matrix materials [8]. These abnor-
malities could not be reproduced in mice that were transgenic
for IGF-I [7]. The severity of glomerulosclerosis in aging rats
correlates with circulating plasma levels of GH [15].
The effect of GH has been studied in various models of
kidney disease. Administration of bovine GH for 10 to 17 days
has no demonstrable effect on the glomerular filtration rate or
renal histopathology in rats with reduced renal mass [16].
Extended rhGH treatment for eight weeks to animals with 5/6
nephrectomy does not alter the inulin clearance; however, it
promotes glomerular hypertrophy and glomerulosclerosis [10].
Genetic deficiency of GH in mutant dwarf rats attenuates the
hypertension, proteinuria and progressive renal parenchymal
destruction following 5/6 nephrectomy compared to the wild
strain with a remnant kidney [9]. In corticosteroid-treated rats
with passive Heymann nephritis that are given rhGH there is no
change in proteinuria or creatinine clearance [17].
It is likely that the potential for GH-induced renal damage is
directly related to the seventy of the underlying disease pro-
cess. In chronic PAMN nephropathy, there is steady exposure
of the glomerulus to the toxin, unremitting injury to glomerular
epithelial cells, mesangial cell dysfunction [18] and more rapid
deterioration in kidney function compared to the experimental
models described above. The proteinuria, hypoalbuminemia
and hyperlipidemia are more severe in chronic PAMN nephrop-
athy than in other experimental models of chronic renal disease.
The level of proteinuria and the biochemical indices of the
nephrotic syndrome were comparable in the two groups of rats
with PAMN nephropathy. This suggests that rhGH treatment
was an additional factor that contributed to the development of
increased kidney damage in rats with glomerular disease.
Following acute intravenous injection of PAMN, provision of
allopurinol, superoxide dismutase, and the hydroxyl radical
scavengers, dimethylthiourea and sodium benzoate, reduces
proteinuria and lessens the renal parenchymal damage [19, 20].
Glucocorticoids enhance the activity of endogenous glomerular
antioxidant enzymes and attenuate lipid peroxidation of glomer-
ular tissue [21]. Reactive oxygen molecules are also involved in
the pathogenesis of chronic PAMN nephropathy. Dietary sup-
plementation with the antioxidant amino acid, taunne, attenu-
ates the structural and functional injury to the kidney, in
conjunction with reduced renal cortical malondialdehyde con-
tent [22]. rhGH may foster increased lipid peroxidation in the
renal parenchyma by stimulating macrophages and mononu-
clear cells that infiltrate the glomeruli and tubulointerstitium of
rats with PAMN nephropathy [23, 24].
The deterioration of kidney function in experimental models
of renal disease may be mediated by alterations in single
nephron blood flow and increased intraglomerular pressure
[25]. Glomerular hypertrophy and the response to circulating,
paracrine, and autocrine peptide growth factors may also con-
tribute to the inexorable loss of renal function [26]. We did not
measure intrarenal hemodynamics in these experiments. How-
ever, the effect of rhGH on glomerular planar area supports the
contention that enlargement of glomeruli per Se plays an pivotal
part in the decline in renal function in animals with chronic
PAMN nephropathy.
Several clinical reports indicate that the use of rhGH results
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Fig. 5. Phofomicrographs illustrating renal histopathology in rats with chronic PAMN nephropathy receiving (A) vehicle (X 120) or (B) rhGH
(x120).
in a dramatic improvement in growth velocity in children with
CRF and short stature [27]. This has been confirmed in a
randomized, double-blind placebo-controlled cross-over clini-
cal trial [28]. No adverse effect of this treatment on renal
function, as reflected by changes in the serum creatinine
concentration, creatinine clearance, or the slope of the l/SCr
versus time plot, has been documented for up to three years of
therapy [4—6, 27—30].
However, as we observed in our study, considerable renal
damage can occur during the course of rhGH therapy that is not
manifested by changes in the serum creatinine concentration
[31]. Furthermore, analogous to experimental kidney disease,
the nephrotoxicity of rhGH in children may be critically depen-
dent upon the severity of the underlying renal disease. The
studies reporting the efficacy of rhGH treatment in children
with CRF include primarily (37 of 51) children with dysplasia,
obstructive uropathy or tubular disorders [4—6, 28, 30]. More-
over, six of the 14 patients with glomerular disease were free of
"massive proteinuria" [28]. Most studies do not stratify pa-
tients according to the antecedent rate of decline in kidney
function. While the potential for renal damage induced by rhGH
may be minimal in children with normal kidney function or
whose renal disease is likely to deteriorate slowly, renal damage
due to rhGH may be exaggerated in pediatric patients whose
CRF is a consequence of severe, rapidly progressive glomeru-
lopathies. In support of this contention, we measured microal-
buminuria in 17 short children with normal renal function who
received rhGH therapy for at least one year. There was no
increase in this sensitive index of glomerular dysfunction com-
pared to 13 growth impaired patients who were not given rhGH
[32]. In addition, the growth rate was accelerated in nine
children with renal transplants treated with rhGH; however,
there was a 24% decline in creatinine clearance during the
course of therapy and treatment was discontinued in two
patients because of a rising serum creatinine [33].
In conclusion, we have demonstrated that administration of
rhGH to rats with chronic PAMN nephropathy results in
diminished renal function, enhanced glomerular hypertrophy
and marked worsening of glomerular sclerosis and tubulointer-
stitial scarring. This deleterious effect on renal function oc-
curred in the absence of any detectable effect of rhGH on blood
pressure, anemia, intermediary metabolism or the severity of
the biochemical indices of the nephrotic syndrome. Although
the numbers of animals that were studied are relatively small
and the duration of follow-up was limited, we suggest that
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Fig. 6. Photomicrographs illustrating the renal histopathology in normal rats receiving (A) vehicle (X 120) or (B) rhGH (X 120).
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